Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Prostate

Retrieve available abstracts of 186 articles:
HTML format
Text format



Single Articles


    June 2017
  1. HE C, Duan S, Dong L, Wang Y, et al
    Characterization of a novel p110beta-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23377.
    PubMed     Text format     Abstract available


  2. CAI B, Chen W, Pan Y, Chen H, et al
    Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23361.
    PubMed     Text format     Abstract available


  3. XU Y, Qin S, An T, Tang Y, et al
    MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Prostate. 2017 Jun 15. doi: 10.1002/pros.23376.
    PubMed     Text format     Abstract available


  4. ZHAO R, Sun F, Bei X, Wang X, et al
    Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients.
    Prostate. 2017 Jun 6. doi: 10.1002/pros.23367.
    PubMed     Text format     Abstract available


  5. ARMSTRONG CM, Liu C, Lou W, Lombard AP, et al
    MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Prostate. 2017;77:1020-1028.
    PubMed     Text format     Abstract available


    May 2017
  6. MORI K, Kimura T, Onuma H, Kimura S, et al
    Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
    Prostate. 2017 May 30. doi: 10.1002/pros.23373.
    PubMed     Text format     Abstract available


  7. KIM Y, Park SE, Moon JW, Kim BM, et al
    Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-kappaB and HSP90 in castration resistant prostate cancer.
    Prostate. 2017 May 30. doi: 10.1002/pros.23370.
    PubMed     Text format     Abstract available


  8. NUNEZ BRAGAYRAC LA, Murekeyisoni C, Vacchio MJ, Attwood K, et al
    Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
    Prostate. 2017 May 26. doi: 10.1002/pros.23364.
    PubMed     Text format     Abstract available


  9. IRIZARRY-RAMIREZ M, Kittles RA, Wang X, Salgado-Montilla J, et al
    Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
    Prostate. 2017 May 24. doi: 10.1002/pros.23368.
    PubMed     Text format     Abstract available


  10. MIYAHIRA AK, Soule HR
    The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2017 May 14. doi: 10.1002/pros.23366.
    PubMed     Text format     Abstract available


    April 2017
  11. SCHALLY AV, Block NL, Rick FG
    Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
    Prostate. 2017 Apr 27. doi: 10.1002/pros.23360.
    PubMed     Text format     Abstract available


  12. CONTEDUCA V, Caffo O, Lolli C, Aieta M, et al
    Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
    Prostate. 2017 Apr 20. doi: 10.1002/pros.23357.
    PubMed     Text format     Abstract available


  13. JIA L, Gui B, Zheng D, Decker KF, et al
    Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23356.
    PubMed     Text format     Abstract available


  14. TANG B, Han CT, Gan HL, Zhang GM, et al
    Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23354.
    PubMed     Text format     Abstract available


  15. PELLEGRINI KL, Patil D, Douglas KJS, Lee G, et al
    Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23355.
    PubMed     Text format     Abstract available


  16. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
    When should active surveillance for prostate cancer stop if no progression is detected?
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23352.
    PubMed     Text format     Abstract available


  17. NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
    Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
    Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
    PubMed     Text format     Abstract available


  18. BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
    External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
    Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
    PubMed     Text format     Abstract available


    March 2017
  19. RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
    Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
    Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
    PubMed     Text format     Abstract available


  20. HABL G, Sauter K, Schiller K, Dewes S, et al
    68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23347.
    PubMed     Text format     Abstract available


  21. WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
    Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23346.
    PubMed     Text format     Abstract available


  22. JOSEFSSON A, Linder A, Flondell Site D, Canesin G, et al
    Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naive Prostate Cancer.
    Prostate. 2017 Mar 10. doi: 10.1002/pros.23325.
    PubMed     Text format     Abstract available


  23. KHAN S, Cai J, Nielsen ME, Troester MA, et al
    The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.
    Prostate. 2017 Mar 6. doi: 10.1002/pros.23342.
    PubMed     Text format     Abstract available


  24. SZULKIN R, Clements MS, Magnusson PK, Wiklund FE, et al
    Estimating Heritability of Prostate Cancer-Specific Survival Using Population-Based Registers.
    Prostate. 2017 Mar 1. doi: 10.1002/pros.23344.
    PubMed     Text format     Abstract available


    February 2017
  25. SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
    Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23326.
    PubMed     Text format     Abstract available


  26. ZHANG Q, Liu S, Ge D, Cunningham DM, et al
    Targeting Th17-IL-17 pathway in prevention of micro-invasive prostate cancer in a mouse model.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23343.
    PubMed     Text format     Abstract available


  27. PILLING AB, Hwang O, Boudreault A, Laurent A, et al
    IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-alpha Signaling.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23327.
    PubMed     Text format     Abstract available


  28. ELSHAFAE SM, Kohart NA, Altstadt LA, Dirksen WP, et al
    The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
    Prostate. 2017 Feb 9. doi: 10.1002/pros.23318.
    PubMed     Text format     Abstract available


  29. VAN DIE MD, Williams SG, Emery J, Bone KM, et al
    A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
    Prostate. 2017 Feb 9. doi: 10.1002/pros.23317.
    PubMed     Text format     Abstract available


  30. LERTSUWAN K, Choe LH, Marwa IR, Lee K, et al
    Identification of Fibulin-1 as a Human Bone Marrow Stromal (HS-5) Sell-Derived Factor That Induces Human Prostate Cancer Cell Death.
    Prostate. 2017 Feb 7. doi: 10.1002/pros.23303.
    PubMed     Text format     Abstract available


  31. NGUYEN HM, Vessella RL, Morrissey C, Brown LG, et al
    LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
    Prostate. 2017 Feb 3. doi: 10.1002/pros.23313.
    PubMed     Text format     Abstract available


  32. ISHARWAL S, Modi S, Arora N, Uhlrich C 3rd, et al
    Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23298.
    PubMed     Text format     Abstract available


  33. DJUSBERG E, Jernberg E, Thysell E, Golovleva I, et al
    High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23307.
    PubMed     Text format     Abstract available


  34. DJALADAT H, Amini E, Xu W, Cai J, et al
    Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23306.
    PubMed     Text format     Abstract available


    January 2017
  35. FITZGERALD LM, Naeem H, Makalic E, Schmidt DF, et al
    Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study.
    Prostate. 2017 Jan 24. doi: 10.1002/pros.23289.
    PubMed     Text format     Abstract available


  36. GRAFF RE, Judson G, Ahearn TU, Fiorentino M, et al
    Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG.
    Prostate. 2017 Jan 19. doi: 10.1002/pros.23312.
    PubMed     Text format     Abstract available


  37. KRATOCHVILOVA M, Raudenska M, Heger Z, Richtera L, et al
    Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression.
    Prostate. 2017 Jan 19. doi: 10.1002/pros.23304.
    PubMed     Text format     Abstract available


  38. CHOPRA A, Georgieva M, Lopes G, Yeo CM, et al
    Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Prostate. 2017 Jan 19. doi: 10.1002/pros.23309.
    PubMed     Text format     Abstract available


  39. WETTSTEIN MS, Saba K, Umbehr MH, Murtola TJ, et al
    Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.
    Prostate. 2017 Jan 17. doi: 10.1002/pros.23296.
    PubMed     Text format     Abstract available


  40. PARIKH RR, Byun J, Goyal S, Kim IY, et al
    Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer.
    Prostate. 2017 Jan 17. doi: 10.1002/pros.23294.
    PubMed     Text format     Abstract available


  41. LEYH-BANNURAH SR, Budaus L, Pompe R, Zaffuto E, et al
    North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer.
    Prostate. 2017 Jan 17. doi: 10.1002/pros.23292.
    PubMed     Text format     Abstract available


    December 2016
  42. ALVA A, Nordquist L, Daignault S, George S, et al
    Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
    Prostate. 2016 Dec 19. doi: 10.1002/pros.23286.
    PubMed     Text format     Abstract available


  43. CHEN M, Zhou B, Zhong P, Rajamanickam V, et al
    Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells.
    Prostate. 2016 Dec 19. doi: 10.1002/pros.23287.
    PubMed     Text format     Abstract available


  44. FOJ L, Ferrer F, Serra M, Arevalo A, et al
    Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis.
    Prostate. 2016 Dec 19. doi: 10.1002/pros.23295.
    PubMed     Text format     Abstract available


  45. SU S, Parris AB, Grossman G, Mohler JL, et al
    Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.
    Prostate. 2016 Dec 14. doi: 10.1002/pros.23288.
    PubMed     Text format     Abstract available


    November 2016
  46. EMAMI NC, Leong L, Wan E, Van Blarigan EL, et al
    Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.
    Prostate. 2016 Nov 30. doi: 10.1002/pros.23283.
    PubMed     Text format     Abstract available


  47. MASKO EM, Alfaqih MA, Solomon KR, Barry WT, et al
    Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
    Prostate. 2016 Nov 30. doi: 10.1002/pros.23282.
    PubMed     Text format     Abstract available


  48. HEMPEL HA, Cuka NS, Kulac I, Barber JR, et al
    Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence.
    Prostate. 2016 Nov 21. doi: 10.1002/pros.23280.
    PubMed     Text format     Abstract available


  49. WANG R, Zeidan AM, Yu JB, Soulos PR, et al
    Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
    Prostate. 2016 Nov 21. doi: 10.1002/pros.23281.
    PubMed     Text format     Abstract available


  50. MALDONADO-CARCELES AB, Sanchez-Rodriguez C, Vera-Porras EM, Arense-Gonzalo JJ, et al
    Anogenital Distance, a Biomarker of Prenatal Androgen Exposure Is Associated With Prostate Cancer Severity.
    Prostate. 2016 Nov 16. doi: 10.1002/pros.23279.
    PubMed     Text format     Abstract available


  51. ARMSTRONG AJ, Humeniuk MS, Healy P, Szmulewitz R, et al
    Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
    Prostate. 2016 Nov 16. doi: 10.1002/pros.23277.
    PubMed     Text format     Abstract available


  52. SULEK JE, Robinson SP, Petrossian AA, Zhou S, et al
    Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.
    Prostate. 2016 Nov 8. doi: 10.1002/pros.23275.
    PubMed     Text format     Abstract available


  53. MIYAZAWA Y, Sekine Y, Kato H, Furuya Y, et al
    Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
    Prostate. 2016 Nov 8. doi: 10.1002/pros.23273.
    PubMed     Text format     Abstract available


  54. GONZALEZ A, Garcia de Durango C, Alonso V, Bravo B, et al
    Distinct Osteomimetic Response of Androgen-Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Implications.
    Prostate. 2016 Nov 3. doi: 10.1002/pros.23270.
    PubMed     Text format     Abstract available


  55. LEE J, Lee MS, Jeoung DI, Kim YM, et al
    Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Prostate. 2016 Nov 3. doi: 10.1002/pros.23274.
    PubMed     Text format     Abstract available


  56. PANG J, Yang YW, Huang Y, Yang J, et al
    P110beta Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
    Prostate. 2016 Nov 1. doi: 10.1002/pros.23271.
    PubMed     Text format     Abstract available


  57. MIYAHIRA AK, Morris M, Soule HR
    Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.
    Prostate. 2016 Nov 1. doi: 10.1002/pros.23272.
    PubMed     Text format     Abstract available


    October 2016
  58. CAPOGROSSO P, Ventimiglia E, Moschini M, Boeri L, et al
    Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine.
    Prostate. 2016 Oct 24. doi: 10.1002/pros.23266.
    PubMed     Text format     Abstract available


  59. JEFFERS A, Sochat V, Kattan MW, Yu C, et al
    Predicting Prostate Cancer Recurrence After Radical Prostatectomy.
    Prostate. 2016 Oct 24. doi: 10.1002/pros.23268.
    PubMed     Text format     Abstract available


  60. DEJIMA T, Imada K, Takeuchi A, Shiota M, et al
    Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.
    Prostate. 2016 Oct 24. doi: 10.1002/pros.23269.
    PubMed     Text format     Abstract available


  61. GEYBELS MS, McCloskey KD, Mills IG, Stanford JL, et al
    Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
    Prostate. 2016 Oct 18. doi: 10.1002/pros.23267.
    PubMed     Text format     Abstract available


  62. DELL'OGLIO P, Karnes RJ, Gandaglia G, Fossati N, et al
    The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.
    Prostate. 2016 Oct 18. doi: 10.1002/pros.23265.
    PubMed     Text format     Abstract available


  63. LEACH DA, Trotta AP, Need EF, Risbridger GP, et al
    The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.
    Prostate. 2016 Oct 8. doi: 10.1002/pros.23259.
    PubMed     Text format     Abstract available


  64. LIU J, Xiao M, Li J, Wang D, et al
    Activation of UPR Signaling Pathway is Associated With the Malignant Progression and Poor Prognosis in Prostate Cancer.
    Prostate. 2016 Oct 8. doi: 10.1002/pros.23264.
    PubMed     Text format     Abstract available


  65. DI SEBASTIANO KM, Pinthus JH, Duivenvoorden WC, Patterson L, et al
    Elevated C-Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer.
    Prostate. 2016 Oct 4. doi: 10.1002/pros.23262.
    PubMed     Text format     Abstract available


  66. SHOAIBI A, Rao GA, Cai B, Rawl J, et al
    Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
    Prostate. 2016 Oct 4. doi: 10.1002/pros.23258.
    PubMed     Text format     Abstract available


  67. IMADA K, Shiota M, Kuroiwa K, Sugimoto M, et al
    FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
    Prostate. 2016 Oct 4. doi: 10.1002/pros.23254.
    PubMed     Text format     Abstract available


  68. OTSUKI H, Kimura T, Yamaga T, Kosaka T, et al
    Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.
    Prostate. 2016 Oct 3. doi: 10.1002/pros.23263.
    PubMed     Text format     Abstract available


  69. TALESA VN, Ferri I, Bellezza G, Love HD, et al
    Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERalpha.
    Prostate. 2016 Oct 3. doi: 10.1002/pros.23261.
    PubMed     Text format     Abstract available


    September 2016
  70. ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
    Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.
    Prostate. 2016 Sep 29. doi: 10.1002/pros.23255.
    PubMed     Text format     Abstract available


  71. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients.
    Prostate. 2016 Sep 29. doi: 10.1002/pros.23253.
    PubMed     Text format     Abstract available


  72. MIYAHIRA AK, Roychowdhury S, Goswami S, Ippolito JE, et al
    Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2016 Sep 28. doi: 10.1002/pros.23260.
    PubMed     Text format     Abstract available


  73. BARRETT CS, Millena AC, Khan SA
    TGF-beta Effects on Prostate Cancer Cell Migration and Invasion Require FosB.
    Prostate. 2016 Sep 7. doi: 10.1002/pros.23250.
    PubMed     Text format     Abstract available


    August 2016
  74. WULANINGSIH W, Astuti Y, Matsuguchi T, Anggrandariyanny P, et al
    Circulating Prostate-Specific Antigen and Telomere Length in a Nationally Representative Sample of Men Without History of Prostate Cancer.
    Prostate. 2016 Aug 27. doi: 10.1002/pros.23245.
    PubMed     Text format     Abstract available


  75. LEE CH, Ku JY, Ha JM, Bae SS, et al
    Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Prostate. 2016 Aug 22. doi: 10.1002/pros.23248.
    PubMed     Text format     Abstract available


  76. CHAKRAVARTHI BV, Goswami MT, Pathi SS, Dodson M, et al
    Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer.
    Prostate. 2016 Aug 22. doi: 10.1002/pros.23243.
    PubMed     Text format     Abstract available


  77. ALBRIGHT FS, Stephenson RA, Agarwal N, Cannon-Albright LA, et al
    Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23247.
    PubMed     Text format     Abstract available


  78. MAUGHAN BL, Luber B, Nadal R, Antonarakis ES, et al
    Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23246.
    PubMed     Text format     Abstract available


  79. ASAI A, Miyata Y, Matsuo T, Shida Y, et al
    Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23244.
    PubMed     Text format     Abstract available


  80. CASTIGLIONE F, Dell'Oglio P, Tosco L, Everaerts W, et al
    Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23242.
    PubMed     Text format     Abstract available


  81. FU W, Tao T, Qi M, Wang L, et al
    MicroRNA-132/212 Upregulation Inhibits TGF-beta-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23241.
    PubMed     Text format     Abstract available


    July 2016
  82. NAKATA D, Nakayama K, Masaki T, Tanaka A, et al
    Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Prostate. 2016 Jul 30. doi: 10.1002/pros.23238.
    PubMed     Text format     Abstract available


  83. BRUCE HM, Stricker PD, Gupta R, Savdie RR, et al
    Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.
    Prostate. 2016 Jul 30. doi: 10.1002/pros.23233.
    PubMed     Text format     Abstract available


  84. CATHOMAS R, Crabb SJ, Mark M, Winterhalder R, et al
    Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
    Prostate. 2016 Jul 25. doi: 10.1002/pros.23236.
    PubMed     Text format     Abstract available


  85. DAI L, Li J, Xing M, Sanchez TW, et al
    Using serological proteome analysis to identify serum anti-nucleophosmin 1 autoantibody as a potential biomarker in European-American and African-American patients with prostate cancer.
    Prostate. 2016 Jul 15. doi: 10.1002/pros.23217.
    PubMed     Text format     Abstract available


  86. KOCEMBA KA, Dudzik P, Ostrowska B, Laidler P, et al
    Incorrect analysis of MCAM gene promoter methylation in prostate cancer.
    Prostate. 2016 Jul 15. doi: 10.1002/pros.23210.
    PubMed     Text format    


  87. WU JC, Wang CT, Hung HC, Wu WJ, et al
    Heteronemin is a novel c-Met/STAT3 inhibitor against advanced prostate cancer cells.
    Prostate. 2016 Jul 15. doi: 10.1002/pros.23230.
    PubMed     Text format     Abstract available


  88. WHITE-AL HABEEB NM, Garcia J, Fleshner N, Bapat B, et al
    Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23235.
    PubMed     Text format     Abstract available


  89. MARKOWSKI MC, Frick KD, Eshleman JR, Luo J, et al
    Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23232.
    PubMed     Text format     Abstract available


  90. AL-BAKHEIT A, Traka M, Saha S, Mithen R, et al
    Accumulation of palmitoylcarnitine and its effect on pro-inflammatory pathways and calcium influx in prostate cancer.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23222.
    PubMed     Text format     Abstract available


  91. FARACH A, Ding Y, Lee M, Creighton C, et al
    Neuronal trans-differentiation in prostate cancer cells.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23221.
    PubMed     Text format     Abstract available


  92. GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
    Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
    Prostate. 2016;76:917-26.
    PubMed     Text format     Abstract available


  93. SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
    Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Prostate. 2016;76:905-16.
    PubMed     Text format     Abstract available


    June 2016
  94. DOGAN A, Demirci S, Turkmen NB, Caglayan AB, et al
    Schiff base-poloxamer P85 combination prevents prostate cancer progression in C57/Bl6 mice.
    Prostate. 2016 Jun 24. doi: 10.1002/pros.23229.
    PubMed     Text format     Abstract available


  95. LIANG P, Henning SM, Schokrpur S, Wu L, et al
    Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression.
    Prostate. 2016 Jun 24. doi: 10.1002/pros.23218.
    PubMed     Text format     Abstract available


  96. SCHWEIZER MT, Wang H, Luber B, Nadal R, et al
    Bipolar androgen therapy for men with androgen ablation naive prostate cancer: Results from the phase II BATMAN study.
    Prostate. 2016 Jun 24. doi: 10.1002/pros.23209.
    PubMed     Text format     Abstract available


  97. CUNNINGHAM D, Parajuli KR, Zhang C, Wang G, et al
    Monomethyl auristatin e phosphate inhibits human prostate cancer growth.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23226.
    PubMed     Text format     Abstract available


  98. KULAC I, Gumuskaya B, Drake CG, Gonzalez B, et al
    Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial .
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23224.
    PubMed     Text format     Abstract available


  99. XIE W, Drouin S, Nakabayashi M, Pomerantz M, et al
    A genetic variation of SOD2 does not determine duration of response to androgen deprivation therapy for prostate cancer.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23220.
    PubMed     Text format     Abstract available


  100. CHENG HH, Klemfuss N, Montgomery B, Higano CS, et al
    A pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23219.
    PubMed     Text format     Abstract available


  101. JUNGHANS RP, Ma Q, Rathore R, Gomes EM, et al
    Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23214.
    PubMed     Text format     Abstract available


  102. MURPHY C, True L, Vakar-Lopez F, Xia J, et al
    A novel system for estimating residual disease and pathologic response to neoadjuvant treatment of prostate cancer.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23215.
    PubMed     Text format     Abstract available


  103. XIAO L, Lanz RB, Frolov A, Castro PD, et al
    The germ cell gene TDRD1 as an ERG target gene and a novel prostate cancer biomarker.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23213.
    PubMed     Text format     Abstract available


  104. SHAHABI A, Lewinger JP, Ren J, April C, et al
    Novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early stage prostate cancer patients.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23211.
    PubMed     Text format     Abstract available


  105. MIYAHIRA AK, Simons JW, Soule HR
    The 22nd annual prostate cancer foundation scientific retreat report.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23193.
    PubMed     Text format     Abstract available


  106. SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
    Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23192.
    PubMed     Text format     Abstract available


  107. SHOURIDEH M, DePriest A, Mohler JL, Wilson EM, et al
    Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23190.
    PubMed     Text format     Abstract available


  108. ANTWI SO, Steck SE, Su LJ, Hebert JR, et al
    Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP).
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23189.
    PubMed     Text format     Abstract available


  109. UDAGER AM, DeMarzo AM, Shi Y, Hicks JL, et al
    Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
    Prostate. 2016;76:845-53.
    PubMed     Text format     Abstract available


  110. PAN X, Zhang X, Gong J, Tan J, et al
    The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.
    Prostate. 2016;76:823-33.
    PubMed     Text format     Abstract available


  111. MCILWAIN DW, Zoetemelk M, Myers JD, Edwards MT, et al
    Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate.
    Prostate. 2016;76:722-34.
    PubMed     Text format     Abstract available


  112. HENNING JD, Bunker CH, Patrick AL, Jenkins FJ, et al
    Human herpesvirus 8 establishes a latent infection in prostates of Tobago men resulting in increased macrophage infiltration.
    Prostate. 2016;76:735-43.
    PubMed     Text format     Abstract available


  113. AKINBOYE ES, Brennen WN, Rosen DM, Bakare O, et al
    Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
    Prostate. 2016;76:703-14.
    PubMed     Text format     Abstract available


    May 2016
  114. ELLIS L, Ku S, Li Q, Azabdaftari G, et al
    Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer.
    Prostate. 2016 May 26. doi: 10.1002/pros.23206.
    PubMed     Text format     Abstract available


  115. GLEICHER S, Kauffman EC, Kotula L, Bratslavsky G, et al
    Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers.
    Prostate. 2016 May 26. doi: 10.1002/pros.23204.
    PubMed     Text format     Abstract available


  116. KRYVENKO ON, Epstein JI
    Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3 + 3 = 6 prostate cancer.
    Prostate. 2016 May 26. doi: 10.1002/pros.23199.
    PubMed     Text format    


  117. CUI T, Hester AG, Seeds MC, Rahbar E, et al
    Impact of genetic and epigenetic variations within the FADS cluster on the composition and metabolism of polyunsaturated fatty acids in prostate cancer.
    Prostate. 2016 May 16. doi: 10.1002/pros.23205.
    PubMed     Text format     Abstract available


  118. MUTHUSWAMY R, Corman JM, Dahl K, Chatta GS, et al
    Functional reprogramming of human prostate cancer to promote local attraction of effector CD8 T cells.
    Prostate. 2016 May 16. doi: 10.1002/pros.23194.
    PubMed     Text format     Abstract available


  119. HECK MM, Thalgott M, Schmid SC, Oh WK, et al
    A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer.
    Prostate. 2016 May 16. doi: 10.1002/pros.23202.
    PubMed     Text format     Abstract available


  120. LYNCH SM, O'Neill KM, McKenna MM, Walsh CP, et al
    Regulation of miR-200c and miR-141 by methylation in prostate cancer.
    Prostate. 2016 May 16. doi: 10.1002/pros.23201.
    PubMed     Text format     Abstract available


  121. CHEN H, Liu X, Brendler CB, Ankerst DP, et al
    Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
    Prostate. 2016 May 16. doi: 10.1002/pros.23200.
    PubMed     Text format     Abstract available


  122. KUMAR D, Gupta A, Mandhani A, Sankhwar SN, et al
    NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
    Prostate. 2016 May 16. doi: 10.1002/pros.23198.
    PubMed     Text format     Abstract available


  123. GREENE DJ, Elshafei A, Nyame YA, Kara O, et al
    External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
    Prostate. 2016 May 16. doi: 10.1002/pros.23197.
    PubMed     Text format     Abstract available


  124. LARBI A, Dallaudiere B, Pasoglou V, Padhani A, et al
    Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
    Prostate. 2016 May 16. doi: 10.1002/pros.23196.
    PubMed     Text format     Abstract available


  125. SAKAI M, Martinez-Arguelles DB, Aprikian AG, Magliocco AM, et al
    De novo steroid biosynthesis in human prostate cell lines and biopsies.
    Prostate. 2016;76:575-87.
    PubMed     Text format     Abstract available


  126. PADMANABHAN A, Rao V, De Marzo AM, Bieberich CJ, et al
    Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants.
    Prostate. 2016;76:523-33.
    PubMed     Text format     Abstract available


  127. BRENNEN WN, Kisteman LN, Isaacs JT
    Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures.
    Prostate. 2016;76:552-64.
    PubMed     Text format     Abstract available


  128. HEGER Z, Gumulec J, Cernei N, Polanska H, et al
    Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines.
    Prostate. 2016;76:679-90.
    PubMed     Text format     Abstract available


    April 2016
  129. VAN NESTE L, Partin AW, Stewart GD, Epstein JI, et al
    Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Prostate. 2016 Apr 28. doi: 10.1002/pros.23191.
    PubMed     Text format     Abstract available


  130. YOSHIKAWA T, Kobori G, Goto T, Akamatsu S, et al
    An original patient-derived xenograft of prostate cancer with cyst formation.
    Prostate. 2016 Apr 21. doi: 10.1002/pros.23188.
    PubMed     Text format     Abstract available


  131. SZARVAS T, Reis H, Vom Dorp F, Tschirdewahn S, et al
    Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
    Prostate. 2016 Apr 7. doi: 10.1002/pros.23186.
    PubMed     Text format     Abstract available


  132. GUAN Y, Wu Y, Liu Y, Ni J, et al
    Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Prostate. 2016 Apr 4. doi: 10.1002/pros.23187.
    PubMed     Text format     Abstract available


  133. TUMMALA R, Nadiminty N, Lou W, Evans CP, et al
    Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.
    Prostate. 2016;76:445-55.
    PubMed     Text format     Abstract available


  134. KESKIVALI T, Kujala P, Visakorpi T, Tammela TL, et al
    Statin use and risk of disease recurrence and death after radical prostatectomy.
    Prostate. 2016;76:469-78.
    PubMed     Text format     Abstract available


    March 2016
  135. CHA YJ, Lee JH, Han HH, Kim BG, et al
    MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.
    Prostate. 2016 Mar 28. doi: 10.1002/pros.23183.
    PubMed     Text format     Abstract available


  136. DE MORREE E, van Soest R, Aghai A, de Ridder C, et al
    Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    Prostate. 2016 Mar 21. doi: 10.1002/pros.23182.
    PubMed     Text format     Abstract available


  137. ROUDIER MP, Winters BR, Coleman I, Lam HM, et al
    Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Prostate. 2016 Mar 16. doi: 10.1002/pros.23171.
    PubMed     Text format     Abstract available


  138. NAM RK, Benatar T, Wallis CJ, Amemiya Y, et al
    MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
    Prostate. 2016 Mar 15. doi: 10.1002/pros.23177.
    PubMed     Text format     Abstract available


  139. CREMERS RG, Aben KK, van Oort IM, Sedelaar JP, et al
    The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.
    Prostate. 2016 Mar 14. doi: 10.1002/pros.23179.
    PubMed     Text format     Abstract available


  140. HERNANDEZ S, Font-Tello A, Juanpere N, de Muga S, et al
    Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Prostate. 2016 Mar 9. doi: 10.1002/pros.23176.
    PubMed     Text format     Abstract available


  141. DING H, Kothandaraman S, Gong L, Williams MM, et al
    A human GRPr-transfected Ace-1 canine prostate cancer model in mice.
    Prostate. 2016 Mar 4. doi: 10.1002/pros.23172.
    PubMed     Text format     Abstract available


  142. ELSHAFAE SM, Hassan BB, Supsavhad W, Dirksen WP, et al
    Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.
    Prostate. 2016 Mar 4. doi: 10.1002/pros.23154.
    PubMed     Text format     Abstract available


  143. TORABI-NEZHAD S, Malekmakan L, Mashayekhi M, Daneshian A, et al
    Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63.
    Prostate. 2016;76:394-401.
    PubMed     Text format     Abstract available


    February 2016
  144. HIJAZI S, Meller B, Leitsmann C, Strauss A, et al
    See the unseen: Mesorectal lymph node metastases in prostate cancer.
    Prostate. 2016 Feb 16. doi: 10.1002/pros.23168.
    PubMed     Text format     Abstract available


  145. FORBES A, Anoopkumar-Dukie S, Chess-Williams R, McDermott C, et al
    Relative cytotoxic potencies and cell death mechanisms of alpha -adrenoceptor antagonists in prostate cancer cell lines.
    Prostate. 2016 Feb 16. doi: 10.1002/pros.23167.
    PubMed     Text format     Abstract available


  146. DOSHI C, Vacchio M, Attwood K, Murekeyisoni C, et al
    Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
    Prostate. 2016 Feb 16. doi: 10.1002/pros.23166.
    PubMed     Text format     Abstract available


  147. HORIGUCHI A, Tsujita K, Irisawa K, Kasamatsu T, et al
    A pilot study of photoacoustic imaging system for improved real-time visualization of neurovascular bundle during radical prostatectomy.
    Prostate. 2016;76:307-15.
    PubMed     Text format     Abstract available


  148. NOSOV A, Reva S, Petrov S, Mamijev E, et al
    Neoadjuvant chemotherapy using reduced-dose docetaxel followed by radical prostatectomy for patients with intermediate and high-risk prostate cancer: a single-center study.
    Prostate. 2016 Feb 11. doi: 10.1002/pros.23165.
    PubMed     Text format     Abstract available


  149. KAWAHARA T, Aljarah AK, Shareef HK, Inoue S, et al
    Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
    Prostate. 2016 Feb 11. doi: 10.1002/pros.23164.
    PubMed     Text format     Abstract available


  150. CHA HR, Lee JH, Hensel JA, Sawant AB, et al
    Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages.
    Prostate. 2016 Feb 9. doi: 10.1002/pros.23155.
    PubMed     Text format     Abstract available


  151. XIE W, Yang M, Chan J, Sun T, et al
    Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
    Prostate. 2016 Feb 5. doi: 10.1002/pros.23160.
    PubMed     Text format     Abstract available


  152. LIU X, Han W, Gulla S, Simon NI, et al
    Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
    Prostate. 2016 Feb 5. doi: 10.1002/pros.23157.
    PubMed     Text format     Abstract available


  153. LYNCH SM, McKenna MM, Walsh CP, McKenna DJ, et al
    miR-24 regulates CDKN1B/p27 expression in prostate cancer.
    Prostate. 2016 Feb 5. doi: 10.1002/pros.23156.
    PubMed     Text format     Abstract available


  154. MELLING N, Taskin B, Hube-Magg C, Kluth M, et al
    Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.
    Prostate. 2016;76:259-72.
    PubMed     Text format     Abstract available


  155. NICKKHOLGH B, Fang X, Winters SM, Raina A, et al
    Cell line modeling to study biomarker panel in prostate cancer.
    Prostate. 2016;76:245-58.
    PubMed     Text format     Abstract available


  156. NIRAULA S, Templeton AJ, Vera-Badillo FE, Joshua AM, et al
    Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Prostate. 2016;76:235-42.
    PubMed     Text format     Abstract available


  157. ARAUJO CL, Quintero IB, Ovaska K, Herrala AM, et al
    Transmembrane prostatic acid phosphatase (TMPAP) delays cells in G1 phase of the cell cycle.
    Prostate. 2016;76:151-62.
    PubMed     Text format     Abstract available


    January 2016
  158. SHUI IM, Kolb S, Hanson C, Sutcliffe S, et al
    Trichomonas vaginalis infection and risk of advanced prostate cancer.
    Prostate. 2016 Jan 28. doi: 10.1002/pros.23153.
    PubMed     Text format     Abstract available


  159. NAKKEN HL, Lephart ED, Hopkins TJ, Shaw B, et al
    Prenatal exposure to soy and selenium reduces prostate cancer risk factors in TRAMP mice more than exposure beginning at six weeks.
    Prostate. 2016 Jan 28. doi: 10.1002/pros.23150.
    PubMed     Text format     Abstract available


  160. VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
    Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naive castration-resistant prostate cancer.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23152.
    PubMed     Text format     Abstract available


  161. HU BR, Fairey AS, Madhav A, Yang D, et al
    AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23151.
    PubMed     Text format     Abstract available


  162. WINCHESTER DA, Gurel B, Till C, Goodman PJ, et al
    Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23147.
    PubMed     Text format     Abstract available


  163. FU X, Zhang W, Su Y, Lu L, et al
    MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23143.
    PubMed     Text format     Abstract available


  164. PAXIMADIS P, Najy AJ, Snyder M, Kim HC, et al
    The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.
    Prostate. 2016 Jan 6. doi: 10.1002/pros.23135.
    PubMed     Text format     Abstract available


  165. HOFNER T, Klein C, Eisen C, Rigo-Watermeier T, et al
    The influence of prostatic anatomy and neurotrophins on basal prostate epithelial progenitor cells.
    Prostate. 2016;76:114-21.
    PubMed     Text format     Abstract available


  166. PEDROSA AR, Graca JL, Carvalho S, Peleteiro MC, et al
    Notch signaling dynamics in the adult healthy prostate and in prostatic tumor development.
    Prostate. 2016;76:80-96.
    PubMed     Text format     Abstract available


  167. CORBIN JM, Overcash RF, Wren JD, Coburn A, et al
    Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.
    Prostate. 2016;76:97-113.
    PubMed     Text format     Abstract available


    December 2015
  168. HERRMANN VL, Wieland DE, Legler DF, Wittmann V, et al
    The STEAP1 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-a new approach to immunotherapy against prostate carcinoma.
    Prostate. 2015 Dec 30. doi: 10.1002/pros.23136.
    PubMed     Text format     Abstract available


  169. KRYVENKO ON, Epstein JI
    Changes in prostate cancer grading: Including a new patient-centric grading system.
    Prostate. 2015 Dec 28. doi: 10.1002/pros.23142.
    PubMed     Text format     Abstract available


  170. KIBEL AS, Ahn J, Isikbay M, Klim A, et al
    Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.
    Prostate. 2015 Dec 28. doi: 10.1002/pros.23139.
    PubMed     Text format     Abstract available


  171. KARATAS OF, Guzel E, Duz MB, Ittmann M, et al
    The role of ATP-binding cassette transporter genes in the progression of prostate cancer.
    Prostate. 2015 Dec 28. doi: 10.1002/pros.23137.
    PubMed     Text format     Abstract available


  172. NADAL R, Tsai HL, Sinibaldi VJ, Paller CJ, et al
    Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
    Prostate. 2015 Dec 22. doi: 10.1002/pros.23141.
    PubMed     Text format     Abstract available


  173. MAGNUSSON LU, Hagberg MT, Plas P, Olsson A, et al
    Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Prostate. 2015 Dec 10. doi: 10.1002/pros.23133.
    PubMed     Text format     Abstract available


  174. MCCROW JP, Petersen DC, Louw M, Chan EK, et al
    Spectrum of mitochondrial genomic variation and associated clinical presentation of prostate cancer in South African men.
    Prostate. 2015 Dec 10. doi: 10.1002/pros.23126.
    PubMed     Text format     Abstract available


  175. RAUSCHENBERGER L, Staar D, Thom K, Scharf C, et al
    Exosomal particles secreted by prostate cancer cells are potent mRNA and protein vehicles for the interference of tumor and tumor environment.
    Prostate. 2015 Dec 8. doi: 10.1002/pros.23132.
    PubMed     Text format     Abstract available


  176. SEEDHOUSE SJ, Affronti HC, Karasik E, Gillard BM, et al
    Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
    Prostate. 2015 Dec 8. doi: 10.1002/pros.23127.
    PubMed     Text format     Abstract available


  177. PAYNE ONDRACEK R, Cheng J, Gangavarapu KJ, Azabdaftari G, et al
    Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue.
    Prostate. 2015;75:1910-5.
    PubMed     Text format     Abstract available


  178. ZAPATA D, Howard LE, Allott EH, Hamilton RJ, et al
    Is PSA related to serum cholesterol and does the relationship differ between black and white men?
    Prostate. 2015;75:1877-85.
    PubMed     Text format     Abstract available


    November 2015
  179. MIYOSHI Y, Uemura H, Umemoto S, Sakamaki K, et al
    Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naive prostate cancer.
    Prostate. 2015 Nov 30. doi: 10.1002/pros.23129.
    PubMed     Text format     Abstract available


  180. BONKHOFF H
    Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer.
    Prostate. 2015 Nov 30. doi: 10.1002/pros.23128.
    PubMed     Text format     Abstract available


  181. NORDSTROM T, Van Blarigan EL, Ngo V, Roy R, et al
    Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.
    Prostate. 2015 Nov 20. doi: 10.1002/pros.23125.
    PubMed     Text format     Abstract available


  182. DIPIPPO VA, Nguyen HM, Brown LG, Olson WC, et al
    Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
    Prostate. 2015 Nov 20. doi: 10.1002/pros.23124.
    PubMed     Text format     Abstract available


  183. HORNING AM, Awe JA, Wang CM, Liu J, et al
    DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Prostate. 2015;75:1790-801.
    PubMed     Text format     Abstract available


  184. NORDBY Y, Andersen S, Richardsen E, Ness N, et al
    Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
    Prostate. 2015;75:1682-93.
    PubMed     Text format     Abstract available


  185. WINTERS B, Plymate S, Zeliadt SB, Holt S, et al
    Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
    Prostate. 2015;75:1694-703.
    PubMed     Text format     Abstract available


    September 2015
  186. LIU Y, Zhao X, Sun X, Li Y, et al
    Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia.
    Prostate. 2015 Sep 10. doi: 10.1002/pros.23058.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: